Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Based on route of administration, the market is categorized into parenteral and oral, where parenteral formulations dominated with a 63.2% share
Its pro-angiogenic mechanism raises a theoretical concern about tumor growth promotion, described in the literature as "a double-edged sword." WADA has banned it as an unapproved substance
FDA, with a review decision expected in late 2026
This distinction is critical for maintaining the bodys natural feedback loops
.png)
US$ 26.73
US$ 24.90
US$ 22.31
US$ 28.04
